» Articles » PMID: 31308656

Ectopic Chondrogenesis of Nude Mouse Induced by Nano Gene Delivery Enhanced Tissue Engineering Technology

Overview
Publisher Dove Medical Press
Specialty Biotechnology
Date 2019 Jul 17
PMID 31308656
Citations 1
Authors
Affiliations
Soon will be listed here.
Abstract

Many techniques and methods have been used clinically to relieve pain from cartilage repair, but the long-term effect is still unsatisfactory.  The objective of this study was to form an artificial chondroid tissue gene enhanced tissue engineering system to repair cartilage defects via nanosized liposomes. Cationic nanosized liposomes were prepared and characterized using transmission electron microscope (TEM) and dynamic laser light scattering (DLS). The rat mesenchymal stem cells (rMSCs) were isolated, cultivated, and induced by SRY (Sex-Determining Region Y)-Box 9 (Sox9) via cationic nanosized liposomes. The induced rMSCs were mixed with a thermo-sensitive chitosan hydrogel and subcutaneously injected into the nude mice. Finally, the newly-formed chondroid tissue obtained in the injection parts, and the transparent parts were detected by HE, collagen II, and safranin O. It was found that the presently prepared cationic nanosized liposomes had the diameter of 85.76±3.48 nm and the zeta potential of 15.76±2.1 mV. The isolated rMSCs proliferation was fibroblast-like, with a cultivated confluence of 90% confluence in 5-8 days, and stained positive for CD29 and CD44 while negative for CD34 and CD45. After transfection with cationic nanosized liposomes, we observed changes of cellular morphology and a higher expression of SOX9 compared with control groups, which indicated that rMSCs could differentiate into chondrocyte in vitro. By mixing transfected rMSCs with the thermo-sensitive hydrogel of chitosan in nude mice, chondroid tissue was successfully obtained, demonstrating that rMSCs can differentiate into chondrogenic cells in vivo. This study explored new ways to improve the quality of tissue engineered cartilage, thus accelerating clinical transformation and reducing patient pain.

Citing Articles

Liposomal Formulations: A Recent Update.

Agrawal S, Baliga V, Londhe V Pharmaceutics. 2025; 17(1).

PMID: 39861685 PMC: 11769406. DOI: 10.3390/pharmaceutics17010036.


Efficient TGF-β1 Delivery to Articular Chondrocytes In Vitro Using Agro-Based Liposomes.

Velot E, Elkhoury K, Kahn C, Kempf H, Linder M, Arab-Tehrany E Int J Mol Sci. 2022; 23(5).

PMID: 35270005 PMC: 8911360. DOI: 10.3390/ijms23052864.

References
1.
Ono K, Saito Y, Yura H, Ishikawa K, Kurita A, Akaike T . Photocrosslinkable chitosan as a biological adhesive. J Biomed Mater Res. 1999; 49(2):289-95. DOI: 10.1002/(sici)1097-4636(200002)49:2<289::aid-jbm18>3.0.co;2-m. View

2.
Sechriest V, Miao Y, Niyibizi C, Matthew H, Evans C, Fu F . GAG-augmented polysaccharide hydrogel: a novel biocompatible and biodegradable material to support chondrogenesis. J Biomed Mater Res. 1999; 49(4):534-41. DOI: 10.1002/(sici)1097-4636(20000315)49:4<534::aid-jbm12>3.0.co;2-#. View

3.
BIQUET V . [Case of relapsing erythroderma psoriaticum with multiple arthropathies and developing into osteolysis]. Arch Belg Dermatol Syphiligr. 1954; 10(1):58-61. View

4.
Donati I, Stredanska S, Silvestrini G, Vetere A, Marcon P, Marsich E . The aggregation of pig articular chondrocyte and synthesis of extracellular matrix by a lactose-modified chitosan. Biomaterials. 2004; 26(9):987-98. DOI: 10.1016/j.biomaterials.2004.04.015. View

5.
Masuoka K, Ishihara M, Asazuma T, Hattori H, Matsui T, Takase B . The interaction of chitosan with fibroblast growth factor-2 and its protection from inactivation. Biomaterials. 2004; 26(16):3277-84. DOI: 10.1016/j.biomaterials.2004.07.061. View